Jonathan Young - 10 Mar 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Operating Officer
Signature
/s/ Jonathan Young
Issuer symbol
AKRO
Transactions as of
10 Mar 2023
Net transactions value
-$27,560
Form type
4
Filing time
14 Mar 2023, 16:19:46 UTC
Previous filing
05 Jan 2023
Next filing
15 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Tax liability $27,560 -634 -0.34% $43.47 184,277 10 Mar 2023 Direct F1
holding AKRO Common Stock 20,000 10 Mar 2023 By EA Irrevocable Trust F2
holding AKRO Common Stock 20,000 10 Mar 2023 By CM Irrevocable Trust F2
holding AKRO Common Stock 20,000 10 Mar 2023 By JL Irrevocable Trust F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares required to be sold to satisfy tax withholding obligations of the Reporting Person related to the vesting of restricted stock units.
F2 These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.